3-fluoro-2-naphthoyl chloride | 33718-14-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-fluoro-2-naphthoyl chloride
• 英文别名: 3-Fluor-2-naphthoylchlorid；3-Fluoro-2-naphthalenecarbonyl chloride；3-fluoronaphthalene-2-carbonyl chloride
• CAS: 33718-14-8
• 化学式: C₁₁H₆ClFO
• 分子量: 208.619
• InChiKey: PGLKCCORLARHIY-UHFFFAOYSA-N

物化性质

• 沸点：
  301.8±15.0 °C(Predicted)
• 密度：
  1.353±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-fluoro-2-naphthoyl chloride 在 盐酸 、 sodium azide 、 溶剂黄146 、 sodium nitrite 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二甲基亚砜 为溶剂， 反应 11.5h， 生成 ethyl 3-methyl-1-(3-methylthio-2-naphthyl)-1H-pyrazole-5-carboxylate
  参考文献：
  名称：

  Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P1 structure–activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides

  摘要：

  Based on DuPont Pharmaceuticals' monobenzamidine lead structure SN429, we have designed the biphenyl 1-(2-naphthyl)-1H-pyrazole-5-carboxylamides as a novel series of non-basic factor Xa inhibitors. We have discovered that the displacement of the benzamidine moiety with substituted 2-naphthyl structures not only results in highly potent factor Xa inhibitors, but also significantly increases their enzyme specificity and oral bioavailability. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00239-1
• 作为产物：
  描述：

  3-氨基-2-萘甲酸 在 盐酸 、 草酰氯 、 N,N-二甲基甲酰胺 、 sodium nitrite 作用下， 以 二氯甲烷 为溶剂， 反应 4.5h， 生成 3-fluoro-2-naphthoyl chloride
  参考文献：
  名称：

  Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P1 structure–activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides

  摘要：

  Based on DuPont Pharmaceuticals' monobenzamidine lead structure SN429, we have designed the biphenyl 1-(2-naphthyl)-1H-pyrazole-5-carboxylamides as a novel series of non-basic factor Xa inhibitors. We have discovered that the displacement of the benzamidine moiety with substituted 2-naphthyl structures not only results in highly potent factor Xa inhibitors, but also significantly increases their enzyme specificity and oral bioavailability. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00239-1

文献信息

• [EN] APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE KINASE DE RÉGULATION DE SIGNAL D'APOPTOSE 1 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ENANTA PHARM INC

  公开号：WO2018218042A1

  公开（公告）日：2018-11-29

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

  本发明揭示了化合物的结构式（I），或者其药学上可接受的盐、酯、立体异构体、互变异构体、溶剂合物、水合物或其组合物：这些化合物可以抑制与自身免疫性疾病、神经退行性疾病、炎症性疾病、慢性肾脏疾病、心血管疾病相关的凋亡信号调节激酶1（ASK-1）。本发明还涉及含有上述化合物的药物组合物，用于治疗患有ASK-1相关疾病的受试者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者中的ASK-1相关疾病的方法。本发明特别涉及治疗与肝脂肪变性相关的ASK-1的方法，包括非酒精性脂肪肝病（NAFLD）和非酒精性脂肪性肝炎病（NASH）。
• 一种有机发光材料、及制法和含该材料的有机发光器件
  申请人：吉林奥来德光电材料股份有限公司

  公开号：CN109369598A

  公开（公告）日：2019-02-22

  本发明涉及发光材料技术领域，具体涉及一种有机发光材料、及制法和含该材料的有机发光器件。本发明为解决上述常规技术存在的问题提供了一种结构新颖的有机发光材料。实现了具有优异的发光效率和显著改进的寿命的有机发光器件。本发明提供的有机发光材料，与常规主体材料相比该化合物具有能显示优异电致发光性质、长的器件寿命和适当色坐标。本发明提供的高效率和长寿命的有机发光器件，该器件使用本发明所述有机发光材料作为电致发光材料。本发明提供的有机发光材料的制法，合成方法简单易行，通过控制反应的温度及时间，可获得高产率的目标产物。
• Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US10253018B2

  公开（公告）日：2019-04-09

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

  本发明公开了式 (I) 化合物或其药学上可接受的盐、酯、立体异构体、同分异构体、溶液剂、水合物或其组合： 其抑制与自身免疫性疾病、神经退行性疾病、炎症性疾病、慢性肾病、心血管疾病相关的凋亡信号调节激酶 1 (ASK-1)。本发明进一步涉及包含上述化合物的药物组合物，用于给患有 ASK-1 相关疾病的患者用药。本发明还涉及通过施用包含本发明化合物的药物组合物治疗受试者 ASK-1 相关疾病的方法。本发明特别涉及治疗与肝脂肪变性相关的ASK-1的方法，包括非酒精性脂肪肝（NAFLD）和非酒精性脂肪性肝炎（NASH）。
• Adcock,W. et al., Australian Journal of Chemistry, 1971, vol. 24, p. 1829 - 1838
  作者：Adcock,W. et al.

  DOI：——

  日期：——
• Ananthakrishnanadar, P.; Varghesedharumaraj, G., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1983, vol. 22, # 5, p. 506 - 507
  作者：Ananthakrishnanadar, P.、Varghesedharumaraj, G.

  DOI：——

  日期：——